Cargando…

Integrated DIA proteomics and lipidomics analysis on non-small cell lung cancer patients with TCM syndromes

BACKGROUND: Lung cancer remains the leading cause of mortality from malignant tumors, non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases, and individualized diagnosis and treatment is an effective trend. The individual characteristics of different traditional Chinese m...

Descripción completa

Detalles Bibliográficos
Autores principales: Cang, Song, Liu, Ran, Jin, Wei, Tang, Qi, Li, Wanjun, Mu, Kunqian, Jin, Pengfei, Bi, Kaishun, Li, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627049/
https://www.ncbi.nlm.nih.gov/pubmed/34838074
http://dx.doi.org/10.1186/s13020-021-00535-x
_version_ 1784606778902708224
author Cang, Song
Liu, Ran
Jin, Wei
Tang, Qi
Li, Wanjun
Mu, Kunqian
Jin, Pengfei
Bi, Kaishun
Li, Qing
author_facet Cang, Song
Liu, Ran
Jin, Wei
Tang, Qi
Li, Wanjun
Mu, Kunqian
Jin, Pengfei
Bi, Kaishun
Li, Qing
author_sort Cang, Song
collection PubMed
description BACKGROUND: Lung cancer remains the leading cause of mortality from malignant tumors, non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases, and individualized diagnosis and treatment is an effective trend. The individual characteristics of different traditional Chinese medicine (TCM) syndromes of NSCLC patients may be revealed by highly specific molecular profiles. METHODS: In this study, 10 NSCLC patients with Qi deficiency and Yin deficiency (QDYD) syndrome and 10 patients with Qi deficiency of lung-spleen (QDLS) syndrome in TNM stage III-IV as well as 10 healthy volunteers were enrolled. Aiming at the varied syndromes of NSCLC patients with “Yin deficiency” as the main difference, a proteomics research based on data-independent acquisition (DIA) was developed. Of the dysregulated proteins in NSCLC patients, lipid metabolism was significantly enriched. Thereafter, nontargeted lipidomics research based on UPLC-Q-TOF/MS was performed in 16 patients, with 8 individuals randomly selected from each syndrome group. Furthermore, the considerably different characteristics between the syndromes and pathological mechanisms of NSCLC were screened by statistical and biological integrations of proteomics and lipidomics and the differential metabolic pathways of the two similar syndromes were further explored. Besides, lipids biomarkers were verified by a clinically used anticancer Chinese medicine, and the level of key differential proteins in the two syndromes was also validated using ELISA. RESULTS: The results showed that glycerophospholipid metabolism, sphingolipid metabolism, glycolipid metabolism, and primary bile acid biosynthesis were altered in NSCLC patients and that glycerophospholipid metabolism was significantly changed between the two syndromes in lipidomics analysis. Among the proteins and lipids, ALDOC and lysophosphatidylcholine (LPCs) were revealed to have a strong relationship by statistical and biological integration analysis, and could effectively distinguish QDLS and QDYD syndromes. Notably, the patients with different syndromes had the most typical metabolic patterns in glycerophospholipid metabolism and glycolysis, reflecting the differences in the syndromes dominated by “Yin deficiency”. CONCLUSIONS: ALDOC and LPCs could be employed for the differentiation of NSCLC patients with QDLS and QDYD syndromes, and “Yin deficiency” might be associated with glycerophospholipid metabolism and glycolysis pathway. The results provided a theoretical basis for “Syndrome differentiation” in TCM diagnosis. Moreover, the developed integrated strategy could also provide a reference for individualized diagnosis and treatment of other diseases. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-021-00535-x.
format Online
Article
Text
id pubmed-8627049
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86270492021-11-30 Integrated DIA proteomics and lipidomics analysis on non-small cell lung cancer patients with TCM syndromes Cang, Song Liu, Ran Jin, Wei Tang, Qi Li, Wanjun Mu, Kunqian Jin, Pengfei Bi, Kaishun Li, Qing Chin Med Research BACKGROUND: Lung cancer remains the leading cause of mortality from malignant tumors, non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases, and individualized diagnosis and treatment is an effective trend. The individual characteristics of different traditional Chinese medicine (TCM) syndromes of NSCLC patients may be revealed by highly specific molecular profiles. METHODS: In this study, 10 NSCLC patients with Qi deficiency and Yin deficiency (QDYD) syndrome and 10 patients with Qi deficiency of lung-spleen (QDLS) syndrome in TNM stage III-IV as well as 10 healthy volunteers were enrolled. Aiming at the varied syndromes of NSCLC patients with “Yin deficiency” as the main difference, a proteomics research based on data-independent acquisition (DIA) was developed. Of the dysregulated proteins in NSCLC patients, lipid metabolism was significantly enriched. Thereafter, nontargeted lipidomics research based on UPLC-Q-TOF/MS was performed in 16 patients, with 8 individuals randomly selected from each syndrome group. Furthermore, the considerably different characteristics between the syndromes and pathological mechanisms of NSCLC were screened by statistical and biological integrations of proteomics and lipidomics and the differential metabolic pathways of the two similar syndromes were further explored. Besides, lipids biomarkers were verified by a clinically used anticancer Chinese medicine, and the level of key differential proteins in the two syndromes was also validated using ELISA. RESULTS: The results showed that glycerophospholipid metabolism, sphingolipid metabolism, glycolipid metabolism, and primary bile acid biosynthesis were altered in NSCLC patients and that glycerophospholipid metabolism was significantly changed between the two syndromes in lipidomics analysis. Among the proteins and lipids, ALDOC and lysophosphatidylcholine (LPCs) were revealed to have a strong relationship by statistical and biological integration analysis, and could effectively distinguish QDLS and QDYD syndromes. Notably, the patients with different syndromes had the most typical metabolic patterns in glycerophospholipid metabolism and glycolysis, reflecting the differences in the syndromes dominated by “Yin deficiency”. CONCLUSIONS: ALDOC and LPCs could be employed for the differentiation of NSCLC patients with QDLS and QDYD syndromes, and “Yin deficiency” might be associated with glycerophospholipid metabolism and glycolysis pathway. The results provided a theoretical basis for “Syndrome differentiation” in TCM diagnosis. Moreover, the developed integrated strategy could also provide a reference for individualized diagnosis and treatment of other diseases. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-021-00535-x. BioMed Central 2021-11-27 /pmc/articles/PMC8627049/ /pubmed/34838074 http://dx.doi.org/10.1186/s13020-021-00535-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Cang, Song
Liu, Ran
Jin, Wei
Tang, Qi
Li, Wanjun
Mu, Kunqian
Jin, Pengfei
Bi, Kaishun
Li, Qing
Integrated DIA proteomics and lipidomics analysis on non-small cell lung cancer patients with TCM syndromes
title Integrated DIA proteomics and lipidomics analysis on non-small cell lung cancer patients with TCM syndromes
title_full Integrated DIA proteomics and lipidomics analysis on non-small cell lung cancer patients with TCM syndromes
title_fullStr Integrated DIA proteomics and lipidomics analysis on non-small cell lung cancer patients with TCM syndromes
title_full_unstemmed Integrated DIA proteomics and lipidomics analysis on non-small cell lung cancer patients with TCM syndromes
title_short Integrated DIA proteomics and lipidomics analysis on non-small cell lung cancer patients with TCM syndromes
title_sort integrated dia proteomics and lipidomics analysis on non-small cell lung cancer patients with tcm syndromes
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627049/
https://www.ncbi.nlm.nih.gov/pubmed/34838074
http://dx.doi.org/10.1186/s13020-021-00535-x
work_keys_str_mv AT cangsong integrateddiaproteomicsandlipidomicsanalysisonnonsmallcelllungcancerpatientswithtcmsyndromes
AT liuran integrateddiaproteomicsandlipidomicsanalysisonnonsmallcelllungcancerpatientswithtcmsyndromes
AT jinwei integrateddiaproteomicsandlipidomicsanalysisonnonsmallcelllungcancerpatientswithtcmsyndromes
AT tangqi integrateddiaproteomicsandlipidomicsanalysisonnonsmallcelllungcancerpatientswithtcmsyndromes
AT liwanjun integrateddiaproteomicsandlipidomicsanalysisonnonsmallcelllungcancerpatientswithtcmsyndromes
AT mukunqian integrateddiaproteomicsandlipidomicsanalysisonnonsmallcelllungcancerpatientswithtcmsyndromes
AT jinpengfei integrateddiaproteomicsandlipidomicsanalysisonnonsmallcelllungcancerpatientswithtcmsyndromes
AT bikaishun integrateddiaproteomicsandlipidomicsanalysisonnonsmallcelllungcancerpatientswithtcmsyndromes
AT liqing integrateddiaproteomicsandlipidomicsanalysisonnonsmallcelllungcancerpatientswithtcmsyndromes